At this pivotal moment, a transformation regarding "AI + weight loss" is quietly taking shape. Currently, the issues of overweight and obesity among residents in China are severe, making it a core topic in public health governance. The state has upgraded weight management as a strategic priority through multiple policies, while AI technology offers breakthrough solutions for scientific weight loss. On October 22, the "Healthy China: AI + Weight Management Pioneering" Industry Collaborative Innovation Seminar was held at the National People's Congress Conference Center. Organized by the China Food and Drug Enterprises Quality Safety Promotion Association, the conference aimed to promote collaboration among "regulatory agencies, academia, and businesses" to establish industry consensus and innovation mechanisms empowered by AI within weight management. Additionally, FANGZHOU JIANKE showcased its practical achievements, providing valuable examples for the industry.
From a capital market perspective, the company's validated profit model and growth potential will continue to garner recognition. With the value of "AI + weight loss" being realized, FANGZHOU JIANKE is expected to become a core player in the "AI + health care" sector.
Dual Drivers of Policy and Demand: "AI + Weight Loss" on the Verge of Explosion
In recent years, the issue of overweight and obesity in China has triggered profound changes in the weight management industry. Abnormal weight is a significant risk factor for chronic diseases such as cardiovascular diseases, diabetes, and certain cancers, threatening public health and increasing the burden on healthcare resources. In this context, the government has continuously launched policies to push for the implementation of weight management: in 2024, the "Weight Management Year" initiative will start with a clear goal of establishing a supportive environment; by April 2025, the National Patriotic Health Campaign Committee will further incorporate health weight management actions into the Healthy China initiative, marking the official entry of weight management into the scope of "national public health governance."
On the demand side, consumers' need for "scientific, effective, and sustainable" weight loss solutions is entering an explosive period. As obesity is often accompanied by various comorbidities, users have an urgent need for scientifically backed weight loss plans, with strong willingness to pay, creating a vast market space. The weight loss process heavily relies on ongoing, personalized interventions and guidance, which aligns perfectly with AI's capabilities in data analysis, program generation, and real-time feedback. Therefore, "AI + weight loss" is regarded as a niche area within chronic disease management that has the shortest implementation path, the most intuitive user experience, and the most certain commercial returns.
From a global perspective, companies like Noom and Hims & Hers Health have already explored mature models in the "AI + weight loss" field. Domestic leading enterprises can not only learn from international experiences but also optimize them to align with Chinese market characteristics, granting them stronger localization advantages. At this stage, China benefits from significant policy support that provides favorable conditions for the popularization of "AI + weight loss," coupled with a larger user base that offers a fertile ground for scalable implementation. As a pioneer in AI + chronic disease management, FANGZHOU JIANKE’s validated business model and technical capabilities adapt well to the Chinese healthcare system, facilitating efficient service for users, while connecting pharmaceutical companies to create a "diagnosis-treatment-drug" closed loop, making its foray into weight management a natural progression.
Technology-Driven: "AI + H2H" System Constructs Unreplicable Competitive Edge
In the "AI + weight loss" segment, FANGZHOU JIANKE's core competitiveness lies in its creation of an "AI technology + ecological network + service capability" integrated "AI + H2H" ecosystem. This system not only connects the entire chain from "users - doctors - pharmaceutical companies," but also enhances the operational efficiency of the entire ecosystem through technological empowerment. Addressing current challenges in weight loss, such as "fragmented solutions, sustainability of effects, and safety assurances," FANGZHOU JIANKE has leveraged its resources and data advantages in chronic disease management to develop the industry's first "AI + weight loss" intelligent solution. Utilizing its self-developed XingShi medical large model as the technological foundation, the AI health manager links both doctors and patients throughout the weight loss service process.
Specifically, when users seek weight loss suggestions, they simply send their health check report, BMI data, and relevant instructions to the AI health manager. It can integrate data regarding age, weight, underlying health conditions, and metabolic indicators to generate personalized weight loss advice. On the other hand, patients with medication needs can receive 24/7 professional answers from the AI medication assistant. For queries involving in-depth medication requirements, the platform can also pair users with qualified medical consultants for responses and follow-ups, ensuring safety and scientific integrity throughout the process.
Beyond technology, the years of resource accumulation by FANGZHOU JIANKE are key to its leadership. As of now, the company’s platform connects 229,000 licensed doctors, over 52.8 million users, and more than 980 pharmaceutical companies, establishing a comprehensive network covering "user demand - doctor services - pharmaceutical supply." For users, this enables rapid matching with appropriate doctors and personalized solutions; for doctors, AI tools enhance efficiency and expand service reach; for pharmaceutical companies, user data provides a precise target audience.
Additionally, unlike many companies in the industry that "explore AI weight loss from scratch," FANGZHOU JIANKE's advantage lies in repurposing established chronic disease management capabilities to weight management scenarios. Previously, it has validated the effectiveness of the "AI + doctor-patient interaction + medication management" model in chronic diseases such as hypertension and diabetes, and weight loss serves as an extension of chronic disease management, allowing direct adoption of core capabilities including doctor-patient communication systems, medication management skills, and user operation experience.
This also gives FANGZHOU JIANKE a significant advantage in practical implementation: weight loss and chronic disease management naturally overlap, as obesity is a catalyst for multiple chronic diseases. Thus, the integration of weight loss plans with chronic disease treatment processes ensures that FANGZHOU JIANKE's accumulated expertise enables it to rapidly scale "AI + weight loss" solutions within the industry.
Simultaneously, FANGZHOU JIANKE's layout of "AI + weight loss" will further enhance its profitability certainty. Its platform’s paying users exhibit clear health management needs and loyalty: with a repurchase rate of 85.4% among paying users and an 81.7% share in prescription medications, indicating a significant demand for long-term professional service support. Coupled with its "familiar doctor-patient" model, the platform has effectively locked in users with strong willingness to pay and high engagement.
Moreover, various key data points in FANGZHOU JIANKE's mid-term performance further underscore the health of its ecosystem and commercial potential: a high repurchase rate reflects users' strong recognition of platform services, while the high proportion of prescription medications showcases the model advantage of integrating weight loss with chronic disease management. Additionally, a 34.4% year-on-year increase in monthly active users indicates that the platform remains in a rapid growth phase. Based on this excellent data, FANGZHOU JIANKE successfully transitioned from losses to profitability in the mid-term of 2025, achieving a net profit of 12.5 million yuan, with adjusted net profits up 16.8% year on year to 17.6 million yuan. This milestone not only marks the mature commercialization of its business model after years of refinement, but also validates the effectiveness of the "AI + H2H" ecosystem in converting business value.
Clearly, AI technology serves not only as the "technical support" for FANGZHOU JIANKE's ecosystem but also as a "value amplifier." On one hand, AI replaces many manual services (such as basic consultations and data organization), lowering service costs and expanding profit margins; on the other hand, through "real-time interactions + data visualization," AI enhances user loyalty, facilitating the transition from "one-time services" to "long-term health management consumption," as well as digging deeper into user needs based on data, extending additional services like health checks and insurance, and constructing a consumption chain of "weight loss - chronic disease management - full-cycle health services."
In conclusion, as we stand in 2025, "AI + weight loss" has entered a critical phase of "scaled implementation." With its validated business model, mature ecosystem, and technological advantages, FANGZHOU JIANKE is poised to become a leader at this stage. From an industry perspective, FANGZHOU JIANKE's practices provide replicable standards for "AI + weight loss," promoting the industry's upgrade from "fragmented services" to "systematic solutions," while its services will aid in popularizing health weight management and reduce service costs through AI, enabling users to access scientifically backed weight loss solutions, striving to reach the goals of the "Weight Management Year." In reality, transitioning from "passive interventions" to "active management," weight management is a long-term, systematic initiative that relies on the strengths of all parties for deep collaboration.
Dr. Xie Fangmin, founder, chairman, and CEO of FANGZHOU JIANKE, stated that the company will always prioritize national core health needs, continuously expand the depth and breadth of "AI + weight loss" applications; it looks forward to collaborating with partners in the fields of healthcare, research, and industry to build a more comprehensive weight management service system, making scientific weight loss accessible to a broader population, and reinforcing the national health defense line.
Overall, driven by the triple forces of policies, demand, and technology, the golden period for the "AI + weight loss" segment has arrived. With the core barriers established through the "AI + H2H" ecosystem, FANGZHOU JIANKE is evolving from an "industry participant" to an "industry leader," likely continuing to deliver value under the Healthy China strategy and facilitating broader implementation of "AI + weight loss," contributing to national health and healthcare sector reform.